Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Peregrine Pharmaceuticals' (NASDAQ:PPHM) Stock Plunges After Problems Found With Cancer Drug Study


Peregrine said it discovered "major discrepancies" involving patient test results. The company blamed a vendor and said it's reviewing the problem.

MINYANVILLE ORIGINAL Peregrine Pharmaceuticals' (NASDAQ:PPHM) stock is plunging after the company said Monday that investors should not rely on previously reported study results for an experimental lung cancer drug because there were problems with the trial.

The company said it discovered "major discrepancies" involving patient test results in a mid-stage study of the experimental drug bavituximab. Peregrine blamed a vendor and said it's reviewing the problem.

"In the meantime, investors should not rely on clinical data that the company disclosed on or before September 7" for its lung cancer trial testing bavituximab, Peregrine says in a statement.

Peregrine is seeking US approval of bavituximab as a second-line treatment for lung cancer. Earlier this month, the company said its drug was shown to extend lives of patients in a study. In fact, it was reported that the drug doubled the time of survival for patients in the trial, an impressive feat that is now very much in question.

Shares dropped more than 85% in pre-market trading Monday morning. The stock soared in recent months, climbing from $0.47 in June to $5.39 a share as of Friday's close.
< Previous
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos